Transgene SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0005175080
EUR
0.95
0.06 (6.73%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Dec 24

  • OPERATING CASH FLOW(Y) Lowest at EUR -58.81 MM
  • ROCE(HY) Lowest at -220.48%
  • PRE-TAX PROFIT(Q) At EUR -20.23 MM has Fallen at -114.93%
2

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 122 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.42

stock-summary
Return on Equity

942.59%

stock-summary
Price to Book

-33.81

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Mar 2013)
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.97%
0%
-21.97%
6 Months
-0.83%
0%
-0.83%
1 Year
23.16%
0%
23.16%
2 Years
-32.67%
0%
-32.67%
3 Years
-48.26%
0%
-48.26%
4 Years
-63.31%
0%
-63.31%
5 Years
-42.58%
0%
-42.58%

Transgene SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-64.00%
EBIT Growth (5y)
-7.36%
EBIT to Interest (avg)
-30.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0.06
Tax Ratio
15.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-43.50
EV to EBIT
-4.06
EV to EBITDA
-4.20
EV to Capital Employed
16.74
EV to Sales
170.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-412.17%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Transgene SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -61.29% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -52.47% vs 32.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-40.70",
          "val2": "-33.80",
          "chgp": "-20.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "0.20",
          "chgp": "750.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.00",
          "val2": "-22.30",
          "chgp": "-52.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,200,114.30%",
          "val2": "-29,891.00%",
          "chgp": "-1,17,022.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
1.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-40.70
-33.80
-20.41%
Interest
1.70
0.20
750.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-34.00
-22.30
-52.47%
Operating Profit Margin (Excl OI)
-1,200,114.30%
-29,891.00%
-1,17,022.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -61.29% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -52.47% vs 32.01% in Dec 2023

stock-summaryCompany CV
About Transgene SA stock-summary
stock-summary
Transgene SA
Pharmaceuticals & Biotechnology
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Company Coordinates stock-summary
Company Details
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166 ILLKIRCH-GRAFFENSTADEN None : 67405
stock-summary
Tel: 33 3 88279100
stock-summary
Registrar Details